CNX Therapeutics, a speciality pharmaceutical company with a focus on improving access to medicines that are critical to the well-being of patients, has successfully completed the acquisition of four cancer support products from Clinigen, a global pharmaceutical services company.
CNX Therapeutics has acquired four medicines; Cardioxane® (dexrazoxane), Savene® (dexrazoxane), Totect® (dexrazoxane) and Ethyol® (amifostine), all of which help mitigate the side effects patients may experience when treated with other cancer therapies.
Cardioxane®, available UK, Europe and global markets, is used in adults with advanced or metastatic breast cancer to prevent long-term harmful effects on the heart caused by treatment with certain anthracyclines.
Savene®, available in the UK and Europe, is used to treat anthracycline extravasation in adults, a rare condition that can impact cancer patients.
Totect®, available in the US, is used for the treatment of anthracycline extravasation as well as for preventing cardiomyopathy associated with doxorubicin in women with metastatic breast cancer.
Ethyol®, available in the US, is used to reduce the cumulative renal toxicity of cisplatin in patients with advanced ovarian cancer and for reduction of the toxic effects of radiation on normal oral tissues in patients with head and neck cancer.
The acquisition of these products represents a significant addition to CNX Therapeutics’ diverse portfolio of critical hospital products. The well-established products are marketed in more than 40 countries which brings expansion to CNX Therapeutics’ global portfolio, complementing their market presence across Europe and bringing new opportunities in Asia, Latin America, North America, Africa and the Middle East.
CNX Therapeutics’ CEO, Guy Clark, said: “The addition of these products to the CNX portfolio strengthens our position as a provider of critically important hospital injectable products, and demonstrates our commitment to improving the lives of patients by ensuring the supply of essential medicines.
“We recognise the great value of these products to prescribers and patients, and are very pleased to partner with Clinigen to transition this important portfolio of products and to ensure ongoing continuity of supply.”
Jerome Charton, Chief Executive Officer of Clinigen, said: “This divestment marks another milestone in Clinigen’s continued strategic evolution towards providing high-value services to the pharmaceutical and biotech sectors.
“These medicines have been integral to Clinigen, but as we refocus our efforts, it is crucial to align our offerings with our core strategy and I’m delighted that CNX Theraputics will be acquiring these brands.”
CNX Therapeutics was acquired by Inflexion Private Equity, a mid-market private equity firm, in 2021.
CNX Therapeutics was advised on this transaction by Trowers & Hamlins, BDO, Grant Thornton and PharmaCloud.
